Genomic Therapy Matching in Rare and Refractory CancersFrank P. Lin, Emily Collignon, Samantha R. Oakes et al.|JAMA Oncology|2026Cited by 6
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.Frank Lin, David M. Thomas, Subotheni Thavaneswaran et al.|Journal of Clinical Oncology|2023Cited by 2
623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12F.P. Lin, David M. Thomas, A. Mersiades et al.|Annals of Oncology|2024Cited by 1
1544P A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterationsM. Kansara, D. Thomas, Subotheni Thavaneswaran et al.|Annals of Oncology|2025Cited by 1
636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudyBenjamin Y. Kong, David Goldstein, D. Espinoza et al.|Annals of Oncology|2024Cited by 0